Cargando…

In Silico Structure-Based Repositioning of Approved Drugs for Spike Glycoprotein S2 Domain Fusion Peptide of SARS-CoV-2: Rationale from Molecular Dynamics and Binding Free Energy Calculations

The membrane-anchored spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a pivotal role in directing the fusion of the virus particle mediated by the host cell receptor angiotensin-converting enzyme 2 (ACE-2). The fusion peptide region of the S protein S2 domain pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Shekhar, Nishant, Sarma, Phulen, Prajapat, Manisha, Avti, Pramod, Kaur, Hardeep, Raja, Anupam, Singh, Harvinder, Bhattacharya, Anusuya, Sharma, Saurabh, Kumar, Subodh, Prakash, Ajay, Medhi, Bikash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511214/
https://www.ncbi.nlm.nih.gov/pubmed/32963099
http://dx.doi.org/10.1128/mSystems.00382-20
_version_ 1783585919201181696
author Shekhar, Nishant
Sarma, Phulen
Prajapat, Manisha
Avti, Pramod
Kaur, Hardeep
Raja, Anupam
Singh, Harvinder
Bhattacharya, Anusuya
Sharma, Saurabh
Kumar, Subodh
Prakash, Ajay
Medhi, Bikash
author_facet Shekhar, Nishant
Sarma, Phulen
Prajapat, Manisha
Avti, Pramod
Kaur, Hardeep
Raja, Anupam
Singh, Harvinder
Bhattacharya, Anusuya
Sharma, Saurabh
Kumar, Subodh
Prakash, Ajay
Medhi, Bikash
author_sort Shekhar, Nishant
collection PubMed
description The membrane-anchored spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a pivotal role in directing the fusion of the virus particle mediated by the host cell receptor angiotensin-converting enzyme 2 (ACE-2). The fusion peptide region of the S protein S2 domain provides SARS-CoV-2 with the biological machinery needed for direct fusion to the host lipid membrane. In our present study, computer-aided drug design strategies were used for the identification of FDA-approved small molecules using the optimal structure of the S2 domain, which exhibits optimal interaction ratios, structural features, and energy variables, which were evaluated based on their performances in molecular docking, molecular dynamics simulations, molecular mechanics/generalized Born model and solvent accessibility binding free energy calculations of molecular dynamics trajectories, and statistical inferences. Among the 2,625 FDA-approved small molecules, chloramphenicol succinate, imipenem, and imidurea turned out to be the molecules that bound the best at the fusion peptide hydrophobic pocket. The principal interactions of the selected molecules suggest that the potential binding site at the fusion peptide region is centralized amid the Lys790, Thr791, Lys795, Asp808, and Gln872 residues. IMPORTANCE The present study provides the structural identification of the viable binding residues of the SARS-CoV-2 S2 fusion peptide region, which holds prime importance in the virus’s host cell fusion and entry mechanism. The classical molecular mechanics simulations were set on values that mimic physiological standards for a good approximation of the dynamic behavior of selected drugs in biological systems. The drug molecules screened and analyzed here have relevant antiviral properties, which are reported here and which might hint toward their utilization in the coronavirus disease 2019 (COVID-19) pandemic owing to their attributes of binding to the fusion protein binding region shown in this study.
format Online
Article
Text
id pubmed-7511214
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-75112142020-10-01 In Silico Structure-Based Repositioning of Approved Drugs for Spike Glycoprotein S2 Domain Fusion Peptide of SARS-CoV-2: Rationale from Molecular Dynamics and Binding Free Energy Calculations Shekhar, Nishant Sarma, Phulen Prajapat, Manisha Avti, Pramod Kaur, Hardeep Raja, Anupam Singh, Harvinder Bhattacharya, Anusuya Sharma, Saurabh Kumar, Subodh Prakash, Ajay Medhi, Bikash mSystems Research Article The membrane-anchored spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a pivotal role in directing the fusion of the virus particle mediated by the host cell receptor angiotensin-converting enzyme 2 (ACE-2). The fusion peptide region of the S protein S2 domain provides SARS-CoV-2 with the biological machinery needed for direct fusion to the host lipid membrane. In our present study, computer-aided drug design strategies were used for the identification of FDA-approved small molecules using the optimal structure of the S2 domain, which exhibits optimal interaction ratios, structural features, and energy variables, which were evaluated based on their performances in molecular docking, molecular dynamics simulations, molecular mechanics/generalized Born model and solvent accessibility binding free energy calculations of molecular dynamics trajectories, and statistical inferences. Among the 2,625 FDA-approved small molecules, chloramphenicol succinate, imipenem, and imidurea turned out to be the molecules that bound the best at the fusion peptide hydrophobic pocket. The principal interactions of the selected molecules suggest that the potential binding site at the fusion peptide region is centralized amid the Lys790, Thr791, Lys795, Asp808, and Gln872 residues. IMPORTANCE The present study provides the structural identification of the viable binding residues of the SARS-CoV-2 S2 fusion peptide region, which holds prime importance in the virus’s host cell fusion and entry mechanism. The classical molecular mechanics simulations were set on values that mimic physiological standards for a good approximation of the dynamic behavior of selected drugs in biological systems. The drug molecules screened and analyzed here have relevant antiviral properties, which are reported here and which might hint toward their utilization in the coronavirus disease 2019 (COVID-19) pandemic owing to their attributes of binding to the fusion protein binding region shown in this study. American Society for Microbiology 2020-09-22 /pmc/articles/PMC7511214/ /pubmed/32963099 http://dx.doi.org/10.1128/mSystems.00382-20 Text en Copyright © 2020 Shekhar et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Shekhar, Nishant
Sarma, Phulen
Prajapat, Manisha
Avti, Pramod
Kaur, Hardeep
Raja, Anupam
Singh, Harvinder
Bhattacharya, Anusuya
Sharma, Saurabh
Kumar, Subodh
Prakash, Ajay
Medhi, Bikash
In Silico Structure-Based Repositioning of Approved Drugs for Spike Glycoprotein S2 Domain Fusion Peptide of SARS-CoV-2: Rationale from Molecular Dynamics and Binding Free Energy Calculations
title In Silico Structure-Based Repositioning of Approved Drugs for Spike Glycoprotein S2 Domain Fusion Peptide of SARS-CoV-2: Rationale from Molecular Dynamics and Binding Free Energy Calculations
title_full In Silico Structure-Based Repositioning of Approved Drugs for Spike Glycoprotein S2 Domain Fusion Peptide of SARS-CoV-2: Rationale from Molecular Dynamics and Binding Free Energy Calculations
title_fullStr In Silico Structure-Based Repositioning of Approved Drugs for Spike Glycoprotein S2 Domain Fusion Peptide of SARS-CoV-2: Rationale from Molecular Dynamics and Binding Free Energy Calculations
title_full_unstemmed In Silico Structure-Based Repositioning of Approved Drugs for Spike Glycoprotein S2 Domain Fusion Peptide of SARS-CoV-2: Rationale from Molecular Dynamics and Binding Free Energy Calculations
title_short In Silico Structure-Based Repositioning of Approved Drugs for Spike Glycoprotein S2 Domain Fusion Peptide of SARS-CoV-2: Rationale from Molecular Dynamics and Binding Free Energy Calculations
title_sort in silico structure-based repositioning of approved drugs for spike glycoprotein s2 domain fusion peptide of sars-cov-2: rationale from molecular dynamics and binding free energy calculations
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511214/
https://www.ncbi.nlm.nih.gov/pubmed/32963099
http://dx.doi.org/10.1128/mSystems.00382-20
work_keys_str_mv AT shekharnishant insilicostructurebasedrepositioningofapproveddrugsforspikeglycoproteins2domainfusionpeptideofsarscov2rationalefrommoleculardynamicsandbindingfreeenergycalculations
AT sarmaphulen insilicostructurebasedrepositioningofapproveddrugsforspikeglycoproteins2domainfusionpeptideofsarscov2rationalefrommoleculardynamicsandbindingfreeenergycalculations
AT prajapatmanisha insilicostructurebasedrepositioningofapproveddrugsforspikeglycoproteins2domainfusionpeptideofsarscov2rationalefrommoleculardynamicsandbindingfreeenergycalculations
AT avtipramod insilicostructurebasedrepositioningofapproveddrugsforspikeglycoproteins2domainfusionpeptideofsarscov2rationalefrommoleculardynamicsandbindingfreeenergycalculations
AT kaurhardeep insilicostructurebasedrepositioningofapproveddrugsforspikeglycoproteins2domainfusionpeptideofsarscov2rationalefrommoleculardynamicsandbindingfreeenergycalculations
AT rajaanupam insilicostructurebasedrepositioningofapproveddrugsforspikeglycoproteins2domainfusionpeptideofsarscov2rationalefrommoleculardynamicsandbindingfreeenergycalculations
AT singhharvinder insilicostructurebasedrepositioningofapproveddrugsforspikeglycoproteins2domainfusionpeptideofsarscov2rationalefrommoleculardynamicsandbindingfreeenergycalculations
AT bhattacharyaanusuya insilicostructurebasedrepositioningofapproveddrugsforspikeglycoproteins2domainfusionpeptideofsarscov2rationalefrommoleculardynamicsandbindingfreeenergycalculations
AT sharmasaurabh insilicostructurebasedrepositioningofapproveddrugsforspikeglycoproteins2domainfusionpeptideofsarscov2rationalefrommoleculardynamicsandbindingfreeenergycalculations
AT kumarsubodh insilicostructurebasedrepositioningofapproveddrugsforspikeglycoproteins2domainfusionpeptideofsarscov2rationalefrommoleculardynamicsandbindingfreeenergycalculations
AT prakashajay insilicostructurebasedrepositioningofapproveddrugsforspikeglycoproteins2domainfusionpeptideofsarscov2rationalefrommoleculardynamicsandbindingfreeenergycalculations
AT medhibikash insilicostructurebasedrepositioningofapproveddrugsforspikeglycoproteins2domainfusionpeptideofsarscov2rationalefrommoleculardynamicsandbindingfreeenergycalculations